TG Therapeutics (TGTX) Financial Analysis & Valuation | Quarter Chart
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclon... more
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, dev... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $8.14B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Michael S. Weiss |
| IPO Date | 2010-05-03 | CAGR | 35.11% |
| Employees | 399 | Website | www.tgtherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.02% | Total Yield | 0.02% |
TGTX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $8.88B | P/E | 19.28 | Forward P/E | 19.65 | PEG | -0.27 |
| P/S | 54064.67 | P/B | 68569.29 | P/CF | -2867719.89 | P/FCF | -3044125.03 |
| Sales | $799.54M | Sales 1Y | 76.08% | Sales 3Y | 3224.34% | Sales 5Y | 33020.8% |
| EPS | $2.76 | EPS 1Y | 638.35% | EPS 3Y | -315.75% | EPS 5Y | -200.74% |
| Sales QoQ | 17.28% | EPS QoQ | -58.33% | Sales QoQ Avg | 14.34% | EPS QoQ Avg | 290.64% |
| Gross Margin | 82.36% | Operating Margin | 17.05% | Profit Margin | 55.22% | ROCE | 10.16% |
| ROA | 29% | ROE | 84% | Altman Z Score | 5.72 | Piotroski Score | 3 |
| Current Ratio | 5.81 | Quick Ratio | 5.12 | Cash Ratio | 2.36 | Op. CF Ratio | -0.1 |
| Debt/Equity | 1.29 | Debt/Assets | 0.49 | Lt Debt/Equity | 1.29 | Lt Debt/Cap. | 0.56 |
| Intrst Cov. | 3.64 | Inventory Turnover | 1.09 | Asset Turnover | 0.52 | Receivables Turnover | 2.04 |
| Enterprise Value | $8.88B | P/E Ratio | 19.28 |
| Forward P/E | 19.65 | PEG Ratio | -0.27 |
| P/S Ratio | 54064.67 | P/B Ratio | 68569.29 |
| P/CF Ratio | -2867719.89 | P/FCF Ratio | -3044125.03 |
| EPS | $2.76 | EPS Growth 1Y | 638.35% |
| EPS Growth 3Y | -315.75% | EPS Growth 5Y | -200.74% |
| Revenue Growth 1Y | 76.08% | Gross Margin | 82.36% |
| Operating Margin | 17.05% | Profit Margin | 55.22% |
| ROE | 84% | ROA | 29% |
| ROCE | 10.16% | Current Ratio | 5.81 |
| Quick Ratio | 5.12 | Cash Ratio | 2.36 |
| Debt/Equity | 1.29 | Interest Coverage | 3.64 |
| Altman Z Score | 5.72 | Piotroski Score | 3 |
TG Therapeutics (TGTX) valuation & financials
TG Therapeutics (TGTX) has a market capitalization of $8.14B and trades at a price-to-earnings ratio of 19.3. It operates in the Healthcare sector (Biotechnology).
TG Therapeutics's revenue grew +76.1% over the last year.
TG Therapeutics's next earnings report is scheduled for November 2, 2026 (provider scheduled date); analysts estimate EPS of $0.37. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)